Another example is that the intergenic single-nucleotide polymorphism of DHFR and FPGS could affect the levels of MTX in the serum, which results in inadequate treatment intensity and disease relapse after HD-MTX treatment in acute lymphoblastic leukemia patients (44). This evidence concerns the gene DHFR and acute lymphoblastic leukemia.